Last reviewed · How we verify
Botulinum toxin serotype A
Botulinum toxin serotype A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin serotype A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum toxin serotype A |
|---|---|
| Sponsor | University of California, Los Angeles |
| Drug class | Neuromuscular blocking agent |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and function is restored.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Glabellar lines and facial wrinkles (cosmetic)
- Spasticity
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Flu-like symptoms
Key clinical trials
- Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia (NA)
- Radiological Evaluation of the Penis Before and After a Botox Injection (PHASE1, PHASE2)
- Assessment of Botulinum Toxin Injection for Treatment of Temporomandibular Joint Dislocation (NA)
- Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex (PHASE4)
- Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects (PHASE3)
- The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex (PHASE4)
- Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars (PHASE2, PHASE3)
- Kinematic-based BoNT-A Injections for Bilateral ET (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin serotype A CI brief — competitive landscape report
- Botulinum toxin serotype A updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI